MoonLake Immunotherapeutics is a clinical-stage biotechnology company developing SLK, a novel tri-specific Nanobody that inhibits both IL-17A and IL-17F for the treatment of inflammatory skin and joint diseases. The company holds an exclusive worldwide license to this proprietary therapy and is advancing SLK through Phase 2 and Phase 3 clinical programs in conditions including hidradenitis suppurativa, psoriatic arthritis, palmoplantar pustulosis, and axial spondyloarthritis, where IL-17 pathway dysfunction drives disease pathology. MoonLake generates no current revenue but plans to commercialize SLK, if approved by regulatory authorities, through direct sales in dermatology and rheumatology markets, earning revenue from future product sales while paying royalties and milestone payments to the licensor.